Subscribe
dmitrii-guzhanin-istockphoto-com-scales--1
Dmitrii_Guzhanin / iStockphoto.com
18 January 2018Europe

Mixed views on Broad’s fate after EPO revokes CRISPR patent

Commentators have offered differing opinions on the impact of yesterday’s decision by the European Patent Office (EPO) to revoke a CRISPR/Cas9 patent owned by the Broad Institute of Harvard and MIT.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Cambridge University signs partnership to address innovation challenges
30 January 2018   The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Biotechnology
Cambridge University signs partnership to address innovation challenges
30 January 2018   The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.

More on this story

Biotechnology
Cambridge University signs partnership to address innovation challenges
30 January 2018   The University of Cambridge has partnered with the University of Copenhagen to address challenges in biomedical innovation law.

More features

Sanofi unit loses genetic disorder patent at EPO after trio of challenges
INTA confirms London as host city for Annual Meeting 2026
INTA unveils key principles on AI and IP rights at Annual Meeting
Illumina takes aim at rival in gene sequencing spat
Novartis tops Big Pharma in global trademark portfolios
PierFerd hires partner with medtech expertise
NanoString to pay 10x Genomics $68m in global settlement
Federal Circuit revives CRISPR feud citing PTAB errors